Detection of HER2 Amplification in Breast Carcinomas: Comparison of Multiplex Ligation-Dependent Probe Amplification MLPA and Fluorescence In Situ Hybridization FISH combined with Automated Spot CountingReportar como inadecuado




Detection of HER2 Amplification in Breast Carcinomas: Comparison of Multiplex Ligation-Dependent Probe Amplification MLPA and Fluorescence In Situ Hybridization FISH combined with Automated Spot Counting - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Cellular Oncology - Volume 28 2006, Issue 4, Pages 151-159

Laboratory for Pathology, PAMM Laboratories, Eindhoven, The Netherlands



Copyright © 2006 Hindawi Publishing Corporation and the authors. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In this study the detection of HER2 gene amplification was evaluated using Fluorescence In Situ Hybridization FISH; PathVysion in comparison with Multiplex Ligation-dependent Probe Amplification MLPA, a PCR based technique. These two methods were evaluated on a series of 46 formalin fixed paraffin embedded breast carcinomas, previously tested for protein overexpression by HercepTest grouped into Hercep 1+, 2+ and 3+. HER2 gene amplification ratio ≥ 2.0 by FISH was found in 9-10, 10-30 and 0-6 in IHC 3+, 2+ and 1+-0 cases, respectively. Digitalized automated spot counting performed with recently developed CW4000 CytoFISH software was 100% concordant with manual FISH scoring. Using MLPA 18-46 samples showed a clear HER2 amplification. Comparing MLPA and IHC showed the same results as for FISH and IHC. All but one FISH positive cases 18-19 were confirmed by MLPA for the presence of the gene amplification. The overall concordance of detection of Her2 gene amplification by FISH and MLPA was 98% 45-46. Furthermore, both the level of amplification and equivocal results correlated well between both methods. In conclusion, MLPA is a reliable and reproducible technique and can be used as an either alternative or additional test to determine HER2 status in breast carcinomas.





Autor: Elna Moerland, Rens L. H. P. M. van Hezik, Toine C. J. M. van der Aa, Mike W. P. M. van Beek, and Adriaan J. C. van den Brule

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados